Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Summary

This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer (mCRPC). Part A uses dose escalation to determine the maximum tolerated dose and/or recommended Phase 2 dose. Part B expands at the selected dose in biomarkerconfirmed disease.

Timeline

Start

2026-03-02

Primary completion

2027-03-14

Completion

2028-06-17

Drugs

Indications